FibroGen, Inc. (FGEN) Stock

About FibroGen, Inc.

FibroGen, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and bringing to market therapies that address significant medical conditions currently lacking effective treatments. Among its pipeline, FibroGen is advancing Roxadustat, an orally administered small molecule that inhibits hypoxia inducible factor prolyl hydroxylases. This drug has successfully completed Phase III clinical trials in the US, Europe, China, and Japan for treating anemia in chronic kidney disease, and is currently in Phase II/III development in China for anemia linked to myelodysplastic syndromes. Additionally, the company is progressing Pamrevlumab, a human monoclonal antibody designed to block connective tissue growth factor. Pamrevlumab is undergoing Phase III clinical development for multiple conditions including idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, with a separate Phase III trial also underway for Duchenne muscular dystrophy. FibroGen maintains strategic collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. Established in 1993, FibroGen, Inc. operates from its headquarters in San Francisco, California.

FibroGen, Inc. is headquartered in US.

FibroGen, Inc. (FGEN) stock trades at $9.07 with a market capitalization of $36.69M. The stock is valued at a price-to-earnings (P/E) ratio of 0.22, a negative price-to-book of -3.95, reflecting negative shareholders' equity, price-to-sales of 4.93. Over the past 52 weeks the stock has ranged between $4.85 and $21.95, and currently trades 58.7% below its 52-week high.

On profitability, FibroGen, Inc. generates a return on equity (ROE) of -267.30% (negative, reflecting a net loss), return on capital employed of -54.95%, an operating margin of -602.22%, a net profit margin of 3050.00%.

Official website: www.fibrogen.com

FibroGen, Inc. by the numbers, 2016–2025

Between 2016 and 2025 FibroGen, Inc. reported revenue of $180.0M rising to $6.0M, a change of -96.7% across 10 years. Compounded, revenue has grown -49.1% a year over five years, -65.1% over three, -80.0% over the last twelve months. Net profit rose to $183.0M.

Operating margin went from -29.9% in 2016 to -712.7% in 2025, a fall of 682.8 percentage points. The most recent net margin is 3050.00%. On a trailing twelve-month basis to Mar '26, revenue is $7.0M and net profit $164.0M.

Borrowings fell from $97.0M to $0, cash on hand is $87.2M, cash from operations was $-5.0M in the latest year, positive in 2 of the last 10.

Return on equity has averaged 1199.3% over five years, and was 4575.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

FibroGen, Inc. (FGEN) — frequently asked questions